We’re a revolutionary, B2B, digital healthcare and SaaS company employing DEEP TECH artificial intelligence enabled, enterprise-level software to automate and scale for sustainable, patent pending, subconscious remodeling for type 2 diabetes and adiposity-based chronic disease remission.
Type 2 diabetes (T2DM) is the apex disease for 10.5% of US healthcare costs of over $300 billion in 2017 at an average total cost of $16,750. In a Phase II completed minimally viable product submitted for publication we achieved 69% (20/29N) T2DM remission on average in 5.3 weeks for 9 1/2 months, which we believe can translate to approximately 50% long-term yearly savings and improved outcomes.
The company is a phase 2 MVP (minimally viable product) and is sight ready in a capital raise to expand for a B2B T2D remission Product Market Fit with a clinical member of the largest ACO in the nation (79,000 lives) out of 11 million. We simplify, scale, and automate virtual T2D remission for enterprises.
Daily Therapy©: 12-weeks automated, self-learning, behavioral, lifestyle, and nutrition podcasts and interactive quizzes start the member’s cognitive AI experience and compliance.
MCI Health® Networks: AI-based, single-click, referral -to- results ecosystem and subconscious remodeling for population health.
Health Factory®: ketogenic protein meal and vitamin distributorship.
Company Information: Dashboards
- T2DM Remission Metrics
- Population Health Remission
- Subconscious Recalibration
- Certified Cost Savings
- Compliance %
- Analytics
- Satisfaction %
Validated cost saving, improved outcomes, satisfaction, and population health metrics are the basis for our growth strategy. Fortune-level enterprise member companies belonging to regional healthcare consortiums and third-party administrators (TPA’s) are actively looking for these results. Our sales team is working with 450 TPA clients and 1 million lives already.
Samuel is a retired heart surgeon. He was an international Principal Investigator for FDA Phase III Trials for ATS Medical, Inc. (ATSI-Nasdaq). He founded University Medical Clinics Inc., a network of primary care clinics contracting with Medicare and HMOs. Samuel co-authored the company’s Daily Therapy© software and was the Investigator for the company’s virtual Phase I/II T2DM remission trials. He’s a graduate of Chicago Medical School.
John Hablak is an experienced and highly effective entrepreneur, having graduated University Colorado in operations management. In 2017 he co-founded and successfully operates the then largest medical marijuana clinic in South Florida. He has since separately acquired a major primary care medical clinic.
Jason is a US Navy veteran and liaison with the web technology and operations teams. He was a network development executive in the HMO industry and formerly COO of University Medical Clinics, Inc. He co-authored the company’s Daily Therapy© software and AI-based personal algorithms. Jason and Samuel co-designed the company’s patent-pending ecosystem.
Nick is acting COO and formerly Southeast US and Northern Caribbean Operations Director for St. Jude Medical and Medtronic. He was charged with contracting and purchasing with some of the country’s largest hospital systems. He is co-founder of Chelexa BioSciences, a patented technology to prevent MRSA, licensed to Hoth Therapeutics (NASDAQ). Nick is a Vietnam veteran serving as a Captain in the US Marine Corp.
October 19, 2021
US and international PCT Patent-pending No. 63/093,618 was granted 10/19/21 entitled “An Artificial-Intelligence based cognitive system and method for modifying Subconscious Brain Habitualization.”
February 3, 2021
A teaming agreement and BAA’s were executed with an internal medicine clinical partner for a 2-year T2DM remission product market fit of 60 matched obese, costly T2D members for certified cost savings and outcomes. Our partner participates in a shared savings contract with a 78,000 person Medicare contracted, accountable care organization (ACO) in Palm Beach … Continued
January 1, 2021
Leveraging IBM Watson Technology to expand our Phase III clinical research for subconscious remodeling, actual cost savings, improved compliance, increased remission, and scale. Our virtual, end-end ecosystem is ready to launch final technology and enrollment steps.
For information, please contact Samuel Sadow, CEO, ssadow@mcihealth.com or 772 233-8183.